NASDAQ: PASGPassage Bio Inc Stock
$1.14-0.01 (-0.87%)
Updated Apr 22, 2024
PASG Price
$1.14
Fair Value Price
-$0.08
Market Cap
$63.38M
52 Week Low
$0.58
52 Week High
$1.79
P/E
-0.61x
P/B
0.57x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$102.06M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.35
Operating Cash Flow
-$78M
Beta
1.21
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PASG Overview
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PASG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PASG ($1.14) is overvalued by 1,461.12% relative to our estimate of its Fair Value price of -$0.08 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PASG ($1.14) is not significantly undervalued (1,461.12%) relative to our estimate of its Fair Value price of -$0.08 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PASG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PASG due diligence checks available for Premium users.
Be the first to know about important PASG news, forecast changes, insider trades & much more!
PASG News
Valuation
PASG fair value
Fair Value of PASG stock based on Discounted Cash Flow (DCF)
Price
$1.14
Fair Value
-$0.08
Undervalued by
1,461.12%
PASG ($1.14) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PASG ($1.14) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PASG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PASG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.61x
Industry
16.21x
Market
41x
PASG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.57x
Industry
5.82x
PASG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PASG's financial health
Profit margin
Revenue
$0.0
Net Income
-$16.8M
Profit Margin
0%
PASG's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$150.5M
Liabilities
$39.3M
Debt to equity
0.35
PASG's short-term assets ($117.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PASG's short-term assets ($117.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PASG's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PASG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.5M
Investing
$7.6M
Financing
$46.0k
PASG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PASG vs Biotech Stocks
Passage Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.